Lipid Disorders
Conference Coverage
ADA: Thiazolidinediones, sulfonylureas best DPP-4s for metformin-based dual GLT
Key clinical point: Adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to metformin in patients with type 2 diabetes was associated with an...
News
FDA panel backs evolocumab for lowering LDL in high-risk patients
Conference Coverage
AACE: Saroglitazar found safe, effective for management of diabetic dyslipidemia
Saroglitazar, currently approved only in India, was found to be an effective drug for the management of glycemic and lipid parameters related to...
Conference Coverage
ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide
Key clinical point: The glucagon-like peptide 1 (GLP-1) receptor agonist lixisenatide does not increase the risk for cardiovascular problems in...
News
FDA panel set to review two biologic lipid-lowering drugs for approval
Conference Coverage
TECOS finds no CV risks for sitagliptin
Key clinical point: Sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor used to lower blood glucose in patients with type 2 diabetes, was not...
News
Tight glycemic control: Somewhat fewer CV events, same mortality
Tight glycemic control does not save lives.
Conference Coverage
Men with cardiac concerns at risk for hypogonadism
Key clinical point: Symptomatic hypogonadism appears to be very common among men with heart problems. Major finding: The rate of symptomatic...
Conference Coverage
OARSI: Chronic conditions complicate osteoarthritis treatment, compliance
Patients with osteoarthritis often have other common chronic conditions, a scenario that has implications for both clinical care and research,...
News
Statins, fibrates lower stroke risk in elderly
Key clinical point: Statin and fibrate therapies significantly decreased stroke risk in a large cohort of elderly people. Major finding: The risk...